Here we urge the adoption of a new paradigm for the design and interpretation of intervention trials in infectious diseases, particularly in emerging infectious disease, that more accurately reflects the dynamics of the transmission process. Interventions in infectious diseases can have indirect effects on those not receiving the intervention as well as direct effects on those receiving the intervention. Combinations of interventions can have complex interactions at the population level. These often cannot be adequately addressed with standard study designs and analytic methods. Simulations can help to accurately represent transmission dynamics in an increasingly complex world which is critical for proper trial design and interpretation. Some ethical aspects of a trial can also be quantified using simulations. After a trial has been conducted, simulations can be used to explore possible explanations for the observed effects. A great deal is to be gained through a multidisciplinary approach that builds collaborations among experts in infectious disease dynamics, epidemiology, statistical science, economics, simulation methods and the conduct of clinical trials.
compare different designs and to identify key aspects critical to its success, thereby improving the choice of design.
Challenges of Designing Intervention Studies for Infectious Diseases and the Role of Simulations
In the design phase of randomized trials of social or biomedical interventions, investigators consider options for how to conduct the trial and ultimately choose the trial population(s), the intervention or control conditions that will occur in each trial arm, the primary and secondary outcomes to be measured, and the way in which randomization will occur. For any set of such choices, a biostatistician working on the study can estimate the range of likely outcomes that could occur in trials of various sizes, then estimate the required sample size to achieve a specified power. This estimate often comes from closed-form equations that produce accurate sample size estimates under defined assumptions about the expected frequency of the outcome in the absence and presence of the intervention, and the amount of variability expected in the outcome within and between the arms of the trial. For many applications outside of infectious diseases, plausible assumptions about these quantities can be made directly based on previous trials, preclinical studies, or theoretical considerations. In particular, for noninfectious diseases, disease frequencies in participants randomized to the control group can reasonably be assumed to be similar to those in groups of individuals not receiving the intervention. Frequencies in those randomized to intervention can be assumed to be the same as those in the control group, reduced by a factor proportional to coverage and adherence of the intervention times the efficacy of the intervention. In infectious diseases, these assumptions are often violated due to the indirect effects of the intervention.
Complications for direct effects
In trials of vaccines and some other measures to prevent infectious diseases, interventions on each trial participant may affect the risk of the outcome on others, both participants and nonparticipants in the trial. For example, recipients of an efficacious vaccine are less likely to become infected but also may be less infectious if they are infected. Infectious diseases are an example of dependent happenings, where the frequency of the outcome depends on the number already affected, which can be changed by intervention [1] . Figure 1 illustrates some of the different effects that might occur in infectious disease interventions [2, 3] . Consider two clusters, or populations, of individuals. In one of the populations, a certain portion of individuals is vaccinated and the rest remain unvaccinated. In the other population, no one is vaccinated.
The direct effect of vaccination in the population in which some individuals were vaccinated is defined by comparing the average outcomes in vaccinated individuals with the average outcomes in unvaccinated individuals. The indirect effects are defined as a contrast between the average outcomes in unvaccinated individuals in the population with vaccination and the average outcomes of unvaccinated individuals in the unvaccinated population. The total effects are defined by comparing the average outcomes in the vaccinated individuals in the vaccinated population to the average outcomes in the unvaccinated individuals in the unvaccinated population. The overall effects are defined by the contrast in the average outcomes in the entire population where some individuals were vaccinated compared to the average outcomes of the entire population that did not receive vaccine.
In the simple Figure 1 , we have not distinguished trial participants from nonparticipants. On the population in which some individuals were vaccinated in Figure 1 , some of the unvaccinated may be in the control arm of the trial, and some may not be in the trial. The indirect effects may reduce the incidence of infection for others within or outside the trial, invalidating the simple assumption that the incidence before the trial will be similar to the incidence in those trial participants who do not receive the intervention. For complex behavioral interventions to reduce infectious disease transmission, such as education programs designed to encourage sexual abstinence to reduce transmission of infections, those who receive the intervention and change their behavior may cause others in the population to change their behaviors in ways that will also affect the risk of participants in the trial. Due to such effects, the mean incidence in each group may depend in complicated ways on the intervention and trial design, which can be addressed with simulations.
Measuring effects beyond the individual level
While the indirect effects discussed above can complicate the design and analysis of intervention trials, measuring them may be of scientific interest beyond, or even instead of, measuring the direct effects of the intervention in protecting individual recipients. Establishing that vaccination provides population-level effects that go beyond the direct effects in the vaccinated can have important consequences for public health policy. Some interventions, such as treatment-as-prevention of HIV, and transmission-blocking malaria vaccines, have only indirect effects. In Figure 1 , the overall effect of an intervention is often the quantity of greatest interest for policy makers, as it summarizes the public health consequences of the choice of intervention strategy if adopted in a population [2] . Establishing that vaccination produces indirect effects in the unvaccinated can make a vaccination strategy more cost-effective. The expected size of these population-level effects depends not only on the size of the direct effect, but also factors related to the transmission of the disease in the population and the distribution of the intervention. Thus, additional tools that account for these interactions may be required to design studies to measure them.
If evaluating population-level effects of interventions, such as the total, indirect or overall effects, is of interest, then a cluster-randomized study will generally be the design of choice [2] . In simple clusterrandomized studies, the clusters are randomized to intervention or control. In two-stage randomized studies, clusters are randomized to one of several possible levels of coverage, also called saturation, of the intervention (possibly zero, or pure control), then individuals within the clusters are randomized to receive or not receive the intervention with probability equal to the coverage assigned to the cluster [4, 5] .
Simulations can examine the properties of different types of cluster-randomized designs, whether parallel, (all randomized at beginning to intervention or control), stepped wedge (the order in which clusters receive intervention is randomized before the trial) [6] , or something else. For example, the ring vaccination trial of an Ebola vaccine compared outcomes in rings of contacts and contacts of contacts around a detected case and randomized each ring to receive either immediate or delayed vaccination [7, 8] . For each type of design, simulations can answer questions such as: what is the required sample size with this design, given the likely degree of transmission during the trial [9] ? What is the optimal choice of cluster size versus number of clusters? What are optimal coverage (saturation) levels across clusters [4] ? Simulations can also compare different types of designs, clarifying the tradeoffs among these designs in power and bias for estimating various quantities of interest. Recently, simulations were used to design a stepped wedge cluster-randomized study of the effectiveness of adding solar-powered mosquito trapping systems to standard malaria interventions, examining different methods of temporally introducing the intervention across an island [10] .
Simulations can also help predict potentially harmful indirect effects. In an intervention where women are encouraged to refuse sexual acts with men, other women in the population, either study participants or nonparticipants, might be sought out by the men refused by women in the trial, known as spillover effects [4] or displacement [11] . If displacement occurs, the incidence of HIV may be higher in the women not benefitting from the intervention than it would have been if the trial had not occurred. In malaria interventions, when some individuals use bednets, the individuals not using bednets may be bitten more often and have increased incidence of malaria. Alternatively, with insecticide-treated bednets, mosquitoes killed because one participant in the intervention arm of a trial uses a treated net, may then fail to bite a person who is in the control arm of the trial, reducing the risk in the control group, thus reducing power.
These spillover effects are part of the dynamic process that can be included in simulations, and thus accounted for in the design phase.
Transmission as a cause of overdispersion
Not only the average risk, but also the variability in risk among individuals receiving a particular intervention may be hard to predict in the infectious disease context. Classical trial sample size calculations rely on simple assumptions about variability for independent events which may be invalid because they do not account for complex social and sexual networks. Because of the dynamics of the transmission process and random events, a group, such as a village or hospital, within an arm of a trial may have many more or many fewer cases than the average value. The amount of this variability may depend on how the trial is designed, for example whether individual persons or groups of persons are randomized to trial arms, and how the intervention is rolled out over time in the trial. For example, in HIV prevention trials, one needs to account for stochastic variation in the spread of HIV from overlapping sexual networks and heterogeneity in biological and behavioral risk factors in addition to the usual variability in standard study design [12] .
Simulations can take into account different sources of variation as well as do sensitivity to unknown sources of variation in calculating sample sizes. 
Combinations of interventions

Heterogeneities in hosts and pathogens
These complexities of trial design can be compounded by additional sources of heterogeneity. Individuals may differ dramatically in both their exposure to infection and their responsiveness to the intervention. Trial planners may have little advance knowledge about the distribution of these sources of variability. Interactions between different pathogen strains can create further variability in risk of the outcome that is difficult to incorporate into simple equations. An example is when a vaccine, such as pneumococcal vaccine, protects against some but not all strains of the pathogen, and individuals who acquire one strain are protected against acquiring another strain, potentially making a vaccine seem more or less efficacious than it is [13] . In addition, infectious diseases have epidemics that have an intrinsic tendency to grow as more people become infected, increasing the risk to others, and eventually to contract as previously susceptible people become infected and immune. Thus the inputs into sample size calculations are a moving target in infectious diseases, sometimes moving quite fast and varying spatially. Sometimes the actual quantities that can be measured from the data observed in a trial are nonlinear functions of the biological efficacy of a vaccine or drug [13, 14, 15] , which may be the quantity of most direct interest or may be the quantity considered most likely to be transportable to populations beyond that in which the trial was conducted.
Simulations can help capture the impact of heterogeneity in the trial population on power and on the size of the effect being measured. For example, heterogeneity in the exposure or susceptibility of trial participants to infection can bias vaccine efficacy estimates toward the null, but simulations showed that under certain assumptions these biases can be avoided by accounting for variation in frailty in the analysis [16] . Simulations taking strain-to-strain interactions into account have demonstrated that even if estimation of heterogeneous protection of each component against pneumococcal carriage fails, unbiased and interpretable estimation of summary measures of vaccine efficacy may still be possible from the observed data [17] .
Improving trial logistics and ethics
Simulations can help identify key elements determining the potential for success of a specific trial, beyond the choice of sample size and outcome measures. These include speed of case ascertainment, test results, or other time-sensitive processes that affect the likelihood of success. Ethical or logistical reasons may motivate the choice of design, particularly for trials in the emerging infectious disease or outbreak setting. The debate over trials of Ebola vaccines during the 2014-5 epidemic in West Africa illustrates that, especially in emergency situations, these considerations may place competing pressures on study design [18] . For example, in the Ebola ring vaccination trial in Guinea, in the face of declining transmission, if cases were not ascertained quickly enough, and the contacts of the cases and the contacts of contacts not found in a timely fashion, then the trial likely would not have been feasible. The ring-vaccination cluster-randomized trial ultimately demonstrated the effectiveness of one Ebola vaccine [7, 8] . The lesson was learned in Ebola to go where the transmission is or where it is expected to be. If vaccination had been allocated randomly in the population, the trial would not have had sufficient power for a conclusive result. Simulations are currently being used to help identify potential sites and study designs for Zika vaccine trials.
Besides being good scientific practice, designing a trial with adequate power is also an ethical requirement.
Underpowered studies create burdens on participants without providing a high degree of assurance that the scientific results will be valuable [19] , while unduly large studies place burdens on too many participants without significant extra benefits from the larger sample size. Poorly considered design runs the risk of discarding interventions that might be useful. Simulations can help find the design that is optimal in terms of either power, speed, or number of deaths/cases averted, that also fulfills ethical requirements for respecting human dignity and other ethical tenets. For example, a cluster-randomized stepped wedge trial was proposed to vaccinate frontline health care workers with a candidate Ebola vaccine as quickly as logistically feasible, but to randomize the order in which each treatment unit received vaccination to allow randomized evaluation of vaccine efficacy. Simulations found that an individually randomized controlled trial that prioritized the highest risk treatment units first indeed would have greater statistical power and speed to a definitive result, avoiding more total health care infections, than the proposed stepped wedge design [20] . This kind of work has a long history in cancer treatment trials [21] , but has been less used in infectious diseases [22, 23] . The expected value of the information from a trial for decision-makers relative to its cost can also be easily calculated using simulation models with an economic component [24] . In the future, interactions among trial designers, epidemiologists, infectious disease modelers, and ethicists may help to specify ethical desiderata for trials and the designs best suited to accomplish these while maintaining ethical treatment of individuals and study validity.
Interpreting Results of a Trial
After a trial, simulations can be helpful in interpreting puzzling or unexpected trial results. A clusterrandomized trial was conducted to compare the effectiveness of isoniazid preventive therapy given on a community-wide basis to standard of care on TB in gold miners in South Africa [25] . Although pre-trial mathematical modeling suggested that the intervention had unusually high potential for TB control [26] , the intervention trial demonstrated no effectiveness on TB. This was thought to be due to lower than expected coin in the computer for every possible event. Each single stochastic simulation produces data similar to that which might be observed in one trial. The simulation results can be stored in a database. From each simulated trial, the effect measures of interest can be estimated using a proposed method of statistical data analysis. The mean estimate over the set of simulations under given assumptions allows assessment of whether the trial will provide an unbiased estimate of the quantity of interest, while variability in the estimates produced over a series of simulated trials provides a measure of the likely variability. Sample size and power calculations can be derived directly from the variability of output of many simulations.
Alternatively, intensity and patterns of variability of disease incidence within the simulated trial can be used as inputs to conventional formulas to calculate the effect size that will be detected in the trial and the sample size required to detect such an effect size given the level of variability.
By changing the assumptions of the simulation, it is possible to explore the sensitivity of the measured effect size or its variability to particular aspects of trial implementation, and thereby to design more efficient trials. By analyzing simulation results with different statistical methods, it is possible to identify potential biases in the analysis that arise from the transmission process.
Choice of simulation approach
A key question is what level of detail is required in the simulation. One can go from full calibration to a country, such as South Africa [35] , to simple simulations with dynamics but little explicit demographic structure [12] . Simplicity needs to be balanced with sufficient detail such that the bias in the results is minimized. One needs to carefully weigh each additional complexity and consider whether the choice of intervention and study design is likely to be affected by it. If comparing analytical approaches only, then purely statistical models may be sufficient, as in [6] . In many contexts, however, dynamic mechanistic models are more useful. In some cases it may be important to consider even within-host effects.
Simulations for designing trials need to choose a contact network structure and critically examine that choice. The choice of network structure used to design an intervention trial can affect the predicted power and needed sample size for the trial. Simulations using networks can examine the effect of within-cluster structure on statistical power and sample size [36] . Simulations can similarly be used to examine the effect of between cluster mixing, that is, contamination across clusters, on the power of a study and bias of estimates.
Incorporating information on network features can improve the efficiency of treatment effect estimation in
cluster-randomized trials [37] . In general, simulation of trials on contact networks can help us understand under what circumstances the structure of these networks matters in trial design and when they can be Concern about robustness of results to model misspecification is often raised. But advice that emanates from a model may still be qualitatively correct even if the model does not accurately characterize all aspects of the transmission system. For example, the advice in trade-offs for optimal design in estimating different effects of interventions in two-staged randomized studies [4] is model-assisted and is used to draw analytical insights that can be valid even if the model is imperfect.
One challenge to using simulations to design and interpret studies is the difficulty in having the appropriate data to inform all aspects of the simulations. This includes empirical epidemiological data about the natural history and transmission of the disease or treatment effect. Simulation can assess the impact of uncertainty or lack of knowledge on potentially important epidemic features. An advantage of using simulations after a trial is that a great deal of additional data will be available to inform the modeling.
In addition to increasing confidence in the choice of population and sample size, the process of designing, implementing and performing the simulations may provide other benefits, such as insight into potential biases in effect estimates, ways to account for heterogeneities in the trial population, calculations of quantities related to the ethics of trial design, and hints about choices in trial design beyond the sample size that may improve the probability of the trial's success. Despite potential caveats, the relative cost of computations versus actually running a trial will be very low, while the potential gains in avoiding inconclusive studies are large.
Conclusions
Expertise in infectious disease dynamics, statistical science, and simulation methods are required to adequately design and interpret trials for many interventions against current and emerging infectious diseases.
Trial design should draw in an expert on infectious disease transmission dynamics, working alongside the statistician who is virtually always employed for study design. Indeed, an increasing number of investigators have both sets of skills. While simulation experiments cannot replace trials, nearly all trials would benefit from simulations, or at least from an exercise to write down the steps in such a simulation, which may in itself point out unexpected aspects of trial design. It is helpful in planning a trial to explicitly write down a timeline of the events in the trial for each case and consider possible variation in the sequence of these events, such as the diagram included in the design of the Ebola ring vaccination trial [7] . Clear communication of complex simulations, the assumptions underlying them and their limitations, is important. In addition to simulating trials prior to implementation, there is value in validating modeling approaches after a trial is completed to develop lessons learned for simulating the next trial. Over the long term, it could be useful to use a combination of simulations and practical experience to develop rules of thumb for adjustment that can be used as guides in smaller studies. Fig. 1 ). • Efficacy/effec-veness es-mators (eg rate vs. risk) Figure 2 : Illustration of simulations used for design and analysis of infectious disease intervention trials.
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